Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses - PubMed (original) (raw)
Clinical Trial
. 2004 Feb 15;103(4):1548-56.
doi: 10.1182/blood-2003-05-1513. Epub 2003 Oct 23.
Affiliations
- PMID: 14576063
- DOI: 10.1182/blood-2003-05-1513
Free article
Clinical Trial
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
Karl S Peggs et al. Blood. 2004.
Free article
Abstract
Data on the application of donor lymphocyte infusions (DLIs) following reduced-intensity transplantation (RIT) remain limited. Persistence of host antigen-presenting cells might increase the efficacy or toxicity of cellular immunotherapies. We report the results of dose-escalating DLIs in 46 patients undergoing RIT, who received a total of 109 infusions to treat mixed chimerism or residual or progressive disease. Diagnoses were myeloma (n = 19), Hodgkin lymphoma (n = 13), non-Hodgkin lymphoma (n = 10), and other (n = 4). Thirty-two had an HLA-matched family donor and 14 an unrelated donor. Grades II to IV graft-versus-host disease (GVHD) occurred in 5 sibling and 7 unrelated donor recipients. GVHD was more common (P =.002), occurred at lower T-cell doses, and was more severe in the unrelated donor cohort. Conversion from mixed to multilineage full donor chimerism occurred in 30 of 35 evaluable patients. Presence of mixed chimerism in the granulocyte lineage at the time of DLI did not predict for chimerism response or GVHD. Disease responses occurred in 63% of patients with myeloma and 70% of those with Hodgkin lymphoma and were not predicted by changes in chimerism. These data support the presence of clinically relevant graft-versus-Hodgkin activity and indicate that DLI may be associated with a significantly increased toxicity in unrelated compared to sibling donor transplant recipients receiving identical treatment protocols.
Comment in
- Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know.
Marks DI, Parker A, Robinson SP. Marks DI, et al. Blood. 2004 Jul 1;104(1):295-6. doi: 10.1182/blood-2004-02-0765. Blood. 2004. PMID: 15208210 No abstract available.
Similar articles
- The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD. Marks DI, et al. Blood. 2002 Nov 1;100(9):3108-14. doi: 10.1182/blood-2002-02-0506. Blood. 2002. PMID: 12384406 - Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K. Peggs KS, et al. Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Clinical Trial. - High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC, Spyridonidis A. Liga M, et al. Biol Blood Marrow Transplant. 2013 Jan;19(1):75-81. doi: 10.1016/j.bbmt.2012.07.021. Epub 2012 Aug 4. Biol Blood Marrow Transplant. 2013. PMID: 22871557 Clinical Trial. - Transplantation tolerance: from theory to clinic.
Fuchs EJ. Fuchs EJ. Immunol Rev. 2014 Mar;258(1):64-79. doi: 10.1111/imr.12154. Immunol Rev. 2014. PMID: 24517426 Free PMC article. Review.
Cited by
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K, Antin JH. Maurer K, et al. Front Immunol. 2024 Mar 15;15:1328858. doi: 10.3389/fimmu.2024.1328858. eCollection 2024. Front Immunol. 2024. PMID: 38558819 Free PMC article. Review. - Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, Halkes CJM, de Wreede LC. Koster EAS, et al. Front Immunol. 2024 Mar 13;15:1335341. doi: 10.3389/fimmu.2024.1335341. eCollection 2024. Front Immunol. 2024. PMID: 38545096 Free PMC article. - Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, Moonim MT, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I. McLornan DP, et al. Leukemia. 2021 Sep;35(9):2445-2459. doi: 10.1038/s41375-021-01294-2. Epub 2021 May 26. Leukemia. 2021. PMID: 34040148 Review. - Immune Tolerance Induction Using Cell-Based Strategies in Liver Transplantation: Clinical Perspectives.
Wang P, Jiang Z, Wang C, Liu X, Li H, Xu D, Zhong L. Wang P, et al. Front Immunol. 2020 Aug 18;11:1723. doi: 10.3389/fimmu.2020.01723. eCollection 2020. Front Immunol. 2020. PMID: 33013824 Free PMC article. Review. - Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
Greiner J, Götz M, Bunjes D, Hofmann S, Wais V. Greiner J, et al. J Clin Med. 2019 Dec 23;9(1):39. doi: 10.3390/jcm9010039. J Clin Med. 2019. PMID: 31878060 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials